M
Mark Lynch
Researcher at Bristol-Myers Squibb
Publications - 69
Citations - 15834
Mark Lynch is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Population. The author has an hindex of 31, co-authored 68 publications receiving 13662 citations. Previous affiliations of Mark Lynch include Smith, Kline & French & Bayer.
Papers
More filters
Journal ArticleDOI
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more
TL;DR: Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Journal ArticleDOI
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
TL;DR: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
Journal ArticleDOI
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm,Christopher A. Carter,Mark Lynch,Timothy B. Lowinger,Jacques Dumas,Roger A. Smith,Brian Schwartz,Ronit Simantov,Susan Kelley +8 more
TL;DR: The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature.
Journal ArticleDOI
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Li Liu,Yichen Cao,Charles Chen,Xiaomei Zhang,Angela McNabola,Dean Wilkie,Scott Wilhelm,Mark Lynch,Christopher A. Carter +8 more
TL;DR: The results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).
Journal ArticleDOI
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
TL;DR: This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting.